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FIELD ACTION REPORT
Bedside Availability of Prepared Oxytocin and Rapid
Administration After Delivery to Prevent Postpartum
Hemorrhage: An Observational Study in Karnataka, India
Corrina Moucheraud,a Jonathon Gass,b Stuart Lipsitz,b,c Jonathan Spector,d Priya Agrawal,a,e
Lisa R Hirschhorn,b,f Atul Gawande,b,c Bhala Kodkanyg
Advance preparation and bedside availability of oxytocin before childbirth was significantly and robustly
associated with rapid administration of the utertonic, as recommended to prevent postpartum hemorrhage.
ABSTRACT
Postpartum hemorrhage is a leading cause of maternal death worldwide. Rapid provision of uterotonics after childbirth
is recommended to reduce the incidence and severity of postpartum hemorrhage. Data obtained through direct
observation of childbirth practices, collected in a study of the World Health Organization’s Safe Childbirth Checklist in
Karnataka, India, were used to measure if oxytocin prepared for administration and available at the bedside before
birth was associated with decreased time to administration after birth. This was an observational study of provider
behavior: data were obtained during a baseline assessment of health worker practices prior to introduction of the Safe
Childbirth Checklist, representing behavior in the absence of any intervention. Analysis was based on 330 vaginal
deliveries receiving oxytocin at any point postpartum. Oxytocin was prepared and available at bedside for
approximately 39% of deliveries. We found that advance preparation and bedside availability of oxytocin was
associated with increased likelihood of oxytocin administration within 1 minute after delivery (adjusted risk ratio=4.89,
95% CI=2.61, 9.16), as well as with decreased overall time to oxytocin administration after delivery (2.9 minutes
sooner in adjusted models, 95% CI= -5.0, -0.9). Efforts to reduce postpartum hemorrhage should include
recommendations and interventions to ensure advance preparation and bedside availability of oxytocin to facilitate
prompt administration of the medicine after birth.
INTRODUCTION
Worldwide, greater than a quarter million mater-nal deaths occur each year,1 and postpartum
hemorrhage (PPH) is the leading direct cause.2
Incidence and severity of PPH can be reduced by active
management of the third stage of labor (AMTSL),
which includes early provision of uterotonics such as
oxytocin.3-5
As a prophylactic intervention, it is essential
that oxytocin be administered as quickly as possible after
childbirth; current guidelines recommend administration
of a uterotonic as part of AMTSL,3 and the International
Confederation of Midwives (ICM) and International
Federation of Gynaecology and Obstetrics (FIGO) recom-
mend oxytocin administration within 1 minute of
delivery.4 Unfortunately, many women globally do not
receive this recommended preventive intervention.6 In
addition, a multicountry study found that, even when
oxytocin is given, there are errors in its administration,
most commonly that administration is delayed beyond
the recommended 1-minute postpartum time frame.7
Multiple studies have quantified poor rates of
adherence to recommended AMTSL guidelines.6-11 In
addition, qualitative research has explored possible causes
of variation in use of AMTSL (including oxytocin
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administration), such as availability of supplies,
lack of and low confidence in skills, and challenges
in preparing and administering oxytocin rapidly
after labor.12-15 However, little is known about
factors associated with the timing of oxytocin use
after delivery. In this investigation, we analyzed
baseline observational data from a quality improve-
ment study, of the Safe Childbirth Checklist (SCC)
program of the World Health Organization (WHO),
to explore whether preparing oxytocin injection
prior to delivery and making it available at bedside
was associated with increased likelihood of its rapid
postpartum use in a hospital in India.
METHODS
Study Design
The SCC, developed by WHO, the Harvard T.H.
Chan School of Public Health, and other partners, is
designed to ensure health care providers’ adherence
to 29 evidence-based essential birth practices in
facility-based peripartum care. A pre-post study of
the SCC in a sub-district hospital in Karnataka,
India, found that an SCC-based intervention
improved adherence to essential birth practices.16
Data Collection
Our analysis uses data from the baseline period of
this SCC study in Karnataka—prior to any
intervention—during the observation period
between delivery and 1-hour postpartum. Data
for the study were collected via direct observation
of health workers providing maternal and new-
born care. Trained data collectors observed birth-
related events during the intrapartum period, at
pre-identified ‘‘pause points’’ between admission
and discharge. Of relevance to this analysis, data
collectors observed and recorded the timing of
childbirth and of oxytocin administration.
Data Analysis
We classified timing of oxytocin administration in
one of three ways:
1. Within 1 minute of delivery (per ICM/FIGO
recommendations)
2. Up to 2 minutes after delivery (broadened
definition of rapid administration)
3. As a continuous value of time (minutes)
between the birth event and postpartum
oxytocin injection
Oxytocin was considered ‘‘prepared and
available at the bedside’’ if it was drawn up into
a syringe and available at the bedside ante-
partum, at the start of pushing.
The sample for this analysis was restricted
to women with normal vaginal deliveries who
received oxytocin at any point postpartum. Multi-
variate models were adjusted for delivery time
(daytime [10:00-16:00] versus nighttime) and
maternal risk factors for hemorrhage (age, parity,
and long labor duration, defined as greater than
12 hours prior to admission for nulliparous women
and greater than 24 hours for all other women).
Univariate analyses were performed using
Rao-Scott chi-square tests.17 Generalized linear
regression models, with a binomial distribution
and a log link function, were used to examine
whether oxytocin was administered within the
recommended 1-minute time frame. For time to
oxytocin administration as a continuous outcome,
we used linear regression modeling.18 All models
included standard errors clustered by provider.
Analyses were conducted using Stata 12.1.
Ethical Review
Study protocols were approved by ethics commit-
tees at Jawaharlal Nehru Medical College in
Karnataka, WHO, the Harvard T.H. Chan School
of Public Health, and the Health Ministry’s Screen-
ing Committee, Indian Council of Medical Research.
RESULTS
Our analyses were based on 330 deliveries.
Oxytocin was prepared and available at bedside
for 38.8% of deliveries (Table 1). Use of oxytocin
within the recommended 1-minute time frame
was higher when prepared oxytocin was available
at bedside than when it was not prepared and
available (15.6% of observed deliveries vs. 3.0%,
respectively; Po .001). We found similar results
when extending the time frame of administra-
tion: oxytocin was given within 2 minutes of
delivery 43.8% of the time when it was prepared
and available at bedside, compared with only
16.3% of the time when it was not (Po .001). The
average time to oxytocin administration when
oxytocin was prepared and available at bedside
was 4.2 minutes—significantly shorter than the
average time of 7.5 minutes when oxytocin was
not prepared and at bedside (Po .001).
Regression models assessing the association
between bedside availability and rapid oxytocin
use suggest that deliveries in which oxytocin was
prepared and available at bedside were nearly
5 times more likely than deliveries in which
Oxytocin should
be administered
as quickly as
possible after
childbirth to
prevent
postpartum
hemorrhage.
Oxytocin was
prepared in
advance and
available at
bedside for 39%
of deliveries.
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oxytocin was not available at bedside to have the
medication administered within 1 minute post-
partum, after adjusting for time of day and
maternal risk factors for hemorrhage (adjusted
risk ratio [RR]= 4.89, 95% confidence interval
[CI]= 2.61, 9.16) (Table 2). When extending the
time frame of administration to 2 minutes after
childbirth, deliveries in which oxytocin had been
prepared and available at bedside were 2.61 times
more likely to have oxytocin administered than
when it was not ready at the bedside (in the
adjusted model, with covariates for time of day
and maternal risk factors for hemorrhage)
(95% CI = 1.26, 5.41). When time was examined
as a continuous variable, deliveries in which
oxytocin was prepared and available at bedside
had oxytocin administered, on average, about
3 minutes sooner than deliveries in which
oxytocin was not ready for administration at
bedside, after adjusting for time of delivery and
maternal hemorrhage risk factors (–2.9 minutes,
95% CI= –5.0, –0.9).
DISCUSSION
Advance preparation and bedside availability of
oxytocin was associated with a significantly
increased likelihood of its rapid use postpartum,
when considering the ICM/FIGO-recommended
1-minute time frame as well as an expanded time
frame of 2 minutes and time-to-use overall.
Covariates representing time of day of the
delivery and maternal risk factors for hemorrhage
did not attenuate this effect.
TABLE 1. Oxytocin Availability at Bedside and Time to Administration Among Vaginal Deliveries Receiving Postpartum
Oxytocin, Karntaka, India (N =330)
Prepared and Available
at Bedside
Not Prepared and
Not Available at Bedside P value
No. (%) 128 (38.8) 202 (61.2)
Received within 1 minute of delivery, No. (%) 20 (15.6) 6 (3.0) o .001
Received within 2 minutes of delivery, No. (%) 56 (43.8) 33 (16.3) o .001
Time to administration, mean (SD) [range], minutes 4.2 (4.6) [0–30] 7.5 (6.2) [0–30] o .001
Time to administration, median (IQR [Q1-Q3]), minutes 3 (25 [0–25]) 5 (29 [1–30]) o .001
Abbreviations: IQR, interquartile range; SD, standard deviation.
TABLE 2. Association Between Time to Oxytocin Administration After Delivery and Bedside Availability of Oxytocin:
Results From Unadjusted and Adjusteda Regression Models Among Vaginal Deliveries Receiving Postpartum Oxytocin,
Karnataka, India (N =330)
RR (95% CI) Adjusted RR (95% CI)
Oxytocin administered within 1 minute 4.99 (2.53, 9.84) 4.89 (2.61, 9.16)
Oxytocin administered within 2 minutes 2.70 (1.38, 5.29) 2.61 (1.26, 5.41)
Minutes (95% CI) Adjusted minutes (95% CI)
Time to oxytocin administration, minutes –3.3 (–5.2, –1.4) –2.9 (–5.0, –0.9)
Abbreviations: CI, confidence interval; RR, risk ratio.
Data for oxytocin administered within 1 minute and 2 minutes report risk ratios from generalized linear models with a binomial distribution and a log link
function; data for time to oxytocin administration report change in number of minutes, from linear regression models.
All results use standard errors clustered by provider.
a Adjusted for time of delivery (daytime/nighttime), mother’s age, parity, long labor (i.e., greater than 12 hours prior to admission for nulliparous women
and greater than 24 hours for all other women).
Advance
preparation and
bedside
availability of
oxytocin was
significantly
associated with
administration
within 1 minute
of delivery.
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Those seeking to implement global guidelines
for the prevention of postpartum hemorrhage
may therefore want to consider adding opera-
tional recommendations to make oxytocin ready
for administration and available at bedside—such
as ensuring adequate supplies of the medication
in the delivery room, preparing oxytocin syringes
in advance, and assigning responsibility to
guarantee these steps are routinely followed.
The advent of prefilled oxytocin syringes (e.g.,
Oxytocin-in-Uniject devices) may facilitate rapid
use after delivery.15,19 An important constraint is
that oxytocin is not heat stable, although recent
evidence from Ghana suggests that it may be
shelf-stable around the point of care.20 So until
additional evidence confirms the parameters of
oxytocin’s stability, hospitals should seek to
extend the cold chain into the labor ward (using
an ice box, for example), so oxytocin can be stored
close to the point of use rather than in general
hospital drug storage. Behavioral prompts for
providers may also be useful, such as keeping an
empty needle and syringe near, or prepackaged in,
the delivery kit. Finally, use of the SCC may help
drive change, as results from the pilot study found
that the intervention increased both pre-labor
preparation of oxytocin and its prompt adminis-
tration to women postpartum.16 Such changes
could help increase the likelihood that health
workers will deliver this potentially lifesaving
intervention to all women in a timely manner.
The findings from this study suggest that health
system constraints and opportunities should be
considered when developing global protocols. Med-
ical practitioners may be responsible for implement-
ing a number of different clinical guidelines—and
policy makers should seek to understand how such
guidelines are used in practice, and whether any
operational challenges might be overcome with
simple procedural solutions. We encourage future
research on the barriers and enablers faced by
health workers and health systems in implement-
ing clinical guidelines to continue to drive improve-
ment in obstetrics and beyond.
Limitations
This study has some limitations. First, data were
observational and collected at only 1 health facility—
so we were able to measure only the association
between bedside availability and timely use, rather
than causality; and the findings may not be
generalizable to all settings. Second, there is the
possibility of measurement error. For example,
without data on facility availability of oxytocin, the
bedside availability variable represents both avail-
ability within the hospital and preparation at bed-
side. To explore the impact of possible measurement
error in the independent variable, we dropped all
births that occurred during time periods when
bedside availability was at or below 10% for 3 days
or longer—as a surrogate indicator of possible stock-
outs—and reran the analyses. This restriction did not
change the main results (likelihood of use within
1 minute of 3.45 [95% CI=1.75, 6.81] when
available at bedside in the fully adjusted model).
Additionally, there were 3 women in the original
dataset who had never received oxytocin postpar-
tum; they were excluded from this analysis, but the
near-universal administration of oxytocin at some
point postpartum suggests that oxytocin was in
stock at the facility at the time of all births studied
here. Third, there is the possibility of omitted variable
bias; however, the results were robust to the
inclusion of covariates that represent risk factors
for complications (which could theoretically be
associated with need for medical care postpartum:
maternal age, parity, and labor duration), although
we cannot eliminate the possibility of confounding
by unobserved variables. Lastly, this analysis did not
assess health outcomes—so while we found that
time to oxytocin administration was shorter when
oxytocin was available and ready for administration
at the bedside than when it was not, it was
impossible to assess whether such improvements
in practice could be expected to result in fewer cases
of PPH and lower mortality.
CONCLUSION
Adherence to global recommendations on prevent-
ing PPH through rapid administration of oxytocin
was much higher when oxytocin was prepared and
at bedside prior to delivery than when it was not.
During the busy immediate postpartum period,
under-resourced health systems with overtaxed
health workers may have the additional need for
such advance planning to enable rapid postpartum
oxytocin administration—which also may have spil-
lover effects to newborns, particularly those with
urgent postpartum care needs. In resource-limited
settings where a single health care worker must care
for both mother and infant, advance preparation of
oxytocin can facilitate rapid administration and thus
avoid interfering with a health worker’s ability to
promptly address the needs of the infant. Simple
interventions, such as advance preparation of
oxytocin and other essential birth supplies before
delivery, are a core component of the SCC, and
Deliveries in which
oxytocin was
available at
bedside received
oxytocin, on
average, about 3
minutes sooner
than when there
was no bedside
oxytocin.
Adding
operational
recommendations
to ensure bedside
availability of
oxytocin at
delivery may help
prevent
postpartum
hemorrhage.
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a study is underway to determine the impact of
these and other critical components of care on
maternal and neonatal morbidity and mortality.
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